Moreover, the PNPLA3 gene variant was even associated with a decreased risk of T2D in the NAFLD patients selected from the NASH CRN study (Speliotes et al., 2010) and a Chinese prospective cohort after adjusting for liver fat content and its changes over time (Xia et al., 2019). The gene discussed is PNPLA3; the disease is metabolic dysfunction-associated steatohepatitis.